AMAG options worldwide rights to Velo's orphan pre-eclampsia candidate; later exercises option, amends deal terms
Velo Bio LLC granted AMAG Pharmaceuticals Inc. an option to exclusive worldwide rights to its digoxin immune fab (DIF) pre-eclampsia (PE) program.
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.